Europe
The new company, which was founded earlier this year, will take a similar approach to treat kidney disease that oncologists have taken with cancer.
A report on the freeze & thaw systems market which considers the global industry analysis 2014 – 2018 and forecast 2019-2029 projects that, the freeze & thaw systems market is expected to reach ~ US$ 270 Mn by the end of 2019 in terms of value, and is forecasted to reach ~ US$ 550 Bn by the end of 2029.
Due to their high accessibility and extensive beneficial properties, human Mesenchymal Stem Cells offer exciting promises in a plethora of applications in regenerative medicine, particularly in cell-based therapies.
Vivoryon Therapeutics AG, will publish its Half Year Results for 2019 on Thursday, August 29, 2019.
Biopharma companies strengthen their senior leadership teams and boards of directors with this week’s appointments.
Biopharma companies large and small are involved in numerous clinical trials. Here’s a look at some of the top stories from last week.
Every week there are numerous scientific studies published. Here’s a look at some of the more interesting ones.
Novo Nordisk filed a lawsuit in a Delaware district court against generic drugmaker Mylan. The suit is an attempt to block Mylan from marketing a generic version of Novo Nordisk’s diabetes drug Victoza.
ViiV Healthcare’s two-month injection proved to be as effective as monthly injections for HIV treatment that are currently on the market, the GlaxoSmithKline subsidiary said this morning as it continues to position itself for a leading share of the market alongside Gilead Sciences.
Fusion Antibodies plc, specialists in pre-clinical antibody discovery, engineering and supply for both therapeutic drug and diagnostic applications, confirms that the Annual Report and Accounts for the year ended 31 March 2019, the Notice of Annual General Meeting and a Form of Proxy will be posted to shareholders later.
PRESS RELEASES